<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Suetens, Carl</style></author><author><style face="normal" font="default" size="100%">Katrien Latour</style></author><author><style face="normal" font="default" size="100%">Tommi Kärki</style></author><author><style face="normal" font="default" size="100%">Enrico Ricchizzi</style></author><author><style face="normal" font="default" size="100%">Pete Kinross</style></author><author><style face="normal" font="default" size="100%">Maria Luisa Moro</style></author><author><style face="normal" font="default" size="100%">Beatrice Jans</style></author><author><style face="normal" font="default" size="100%">Susan Hopkins</style></author><author><style face="normal" font="default" size="100%">Sonja Hansen</style></author><author><style face="normal" font="default" size="100%">Lyytikäinen, Outi</style></author><author><style face="normal" font="default" size="100%">Jacqui Reilly</style></author><author><style face="normal" font="default" size="100%">Aleksander Deptula</style></author><author><style face="normal" font="default" size="100%">Walter Zingg</style></author><author><style face="normal" font="default" size="100%">Plachouras, Diamantis</style></author><author><style face="normal" font="default" size="100%">Dominique L Monnet</style></author><author><style face="normal" font="default" size="100%">Eline Vandael</style></author><author><style face="normal" font="default" size="100%">Boudewijn Catry</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">the Healthcare-Associated Infections Prevalence Study Group</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017</style></title><secondary-title><style face="normal" font="default" size="100%">Eurosurveillance</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute care hospitals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antimicrobial resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">antimicrobial use</style></keyword><keyword><style  face="normal" font="default" size="100%">Healthcare-associated infection</style></keyword><keyword><style  face="normal" font="default" size="100%">long-term care facilities</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2018</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Mar-11-2019</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">23</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Point prevalence surveys of healthcare-associated infections (HAI) and antimicrobial use in the European Union and European Economic Area (EU/EEA) from 2016 to 2017 included 310,755 patients from 1,209 acute care hospitals (ACH) in 28 countries and 117,138 residents from 2,221 long-term care facilities (LTCF) in 23 countries. After national validation, we estimated that 6.5% (cumulative 95% confidence interval (cCI): 5.4–7.8%) patients in ACH and 3.9% (95% cCI: 2.4–6.0%) residents in LTCF had at least one HAI (country-weighted prevalence). On any given day, 98,166 patients (95% cCI: 81,022–117,484) in ACH and 129,940 (95% cCI: 79,570–197,625) residents in LTCF had an HAI. HAI episodes per year were estimated at 8.9 million (95% cCI: 4.6–15.6 million), including 4.5 million (95% cCI: 2.6–7.6 million) in ACH and 4.4 million (95% cCI: 2.0–8.0 million) in LTCF; 3.8 million (95% cCI: 3.1–4.5 million) patients acquired an HAI each year in ACH. Antimicrobial resistance (AMR) to selected AMR markers was 31.6% in ACH and 28.0% in LTCF. Our study confirmed a high annual number of HAI in healthcare facilities in the EU/EEA and indicated that AMR in HAI in LTCF may have reached the same level as in ACH.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">46</style></issue></record></records></xml>